# Where Healthcare Capital is Actually Moving in 2026 > I spoke at the Global Health Exhibition Capital Xchange webinar opened by the Saudi Ministry of Health, and the headline story in healthcare venture this year is concentration — less capital, larger checks, AI dominating in techbio and clinical workflows, and a Saudi market that is shifting from consumer to producer economy. URL: https://www.ch-healthtech.com/insights/where-healthcare-capital-actually-moving-2026 Markdown: https://www.ch-healthtech.com/insights/where-healthcare-capital-actually-moving-2026.md Published: 2026-05-14 Author: Christian Hein Tags: technology/artificial-intelligence, technology/digital-health, technology/foundation-models, industry/tech-bio, industry/health-tech, geography/middle-east-gcc --- ## TL;DR Healthcare venture capital has reset hard — $7B raised by healthcare-focused VCs in 2025, down from a $41B peak in 2021 — and the result is concentration: bigger checks into fewer companies, with AI absorbing the largest share. Techbio and AI-native clinical workflow companies are capturing most of the megarounds, while pure telehealth and AI-veneer plays are being actively rotated out. Saudi Arabia is quietly executing a structural shift from healthcare consumer to healthcare producer, which changes the terms of engagement for any foreign company looking at the region. --- Notes from the Global Health Exhibition Capital Xchange webinar where I spoke yesterday, opened by the Saudi Ministry of Health, May 2026. The headline story in healthcare venture this year is concentration. Capital supply has reset, the share going to AI has expanded, and a small number of techbio and AI-native clinical workflow companies are absorbing most of the megarounds. Underneath that, Saudi Arabia is quietly rebuilding its healthcare investment thesis from consumer spending to domestic production. ## The capital reset is real and disciplined Healthcare-focused VCs raised around $7B in 2025, down from the $41B peak in 2021. Less money is chasing healthcare, which means more discipline on what gets backed and bigger checks into fewer companies. The dynamic is concentration. ## AI now takes the largest share SVB estimates AI represented 46% of healthcare venture investment in 2025. CB Insights reported $7.4B of digital health funding in Q1 2026 alone, concentrated across 19 megarounds. The question has shifted from whether AI will get funded in healthcare to which categories within AI are crossing into compounding revenue. ## Techbio and AI drug discovery is the new megaround category Earendil Labs raised $787M in March with Sanofi and the Pfizer-Hillhouse Biotech Development Fund. Takeda committed $1.7B to Iambic in February. Isomorphic closed a $2.1B Series B this week. Sovereign wealth and pharma corporate venture are now co-anchoring frontier deals together, which changes the syndicate dynamics and the exit horizon for everyone else around the table. ## AI-native clinical workflows have crossed into production OpenEvidence is at a $12B valuation, reportedly used daily by more than 40% of US physicians. Ambient documentation is now default at major US health systems. This is workflow infrastructure in production, and it will set the bar for what credible AI in clinical settings looks like for the next decade. ## Where the caution sits Pure telehealth, digital therapeutics, and AI-veneer companies without distinctive proprietary data or workflow defensibility are the part of the portfolio that capital is actively rotating away from. If the moat is a model wrapper and a UI, the 2026 financing environment is unforgiving. ## The Saudi shift from consumer to producer economy The most structurally interesting thread came from the keynote by Ezzedine Zaatari and Yasser Almahmoud at the Saudi Ministry of Health. Saudi Arabia's healthcare investment thesis is moving from a consumer economy to a producer economy. The components are domestic R&D, regulatory streamlining, localised manufacturing, and a reinvestment loop where every cycle compounds. The stated ambition is a self-reinforcing innovation flywheel. For foreign techbio and AI plays looking at the region, this matters. The terms of engagement are shifting from market access to co-development and local presence. The capital is there, the regulatory posture is becoming more constructive, and the buyer is now also a builder. That changes how to structure a partnership, how to think about IP residency, and how to plan a local entity. ## Net read for 2026 Less capital, larger checks, AI concentrated in techbio and clinical workflow infrastructure, sovereign and pharma money co-anchoring frontier deals, and a Saudi market that wants you in the country rather than only selling into it. ## Key takeaways - Healthcare-focused VCs raised around $7B in 2025, down from the $41B peak in 2021 — the result is more discipline and bigger checks into fewer companies. - AI represented 46% of healthcare venture investment in 2025 (SVB), with $7.4B of digital health funding in Q1 2026 alone concentrated across just 19 megarounds. - Sovereign wealth and pharma corporate venture are now co-anchoring frontier techbio deals together, changing syndicate dynamics and exit horizons for everyone else at the table. - AI-native clinical workflow tools like OpenEvidence are already in production at scale — this sets the bar for what credible AI in clinical settings looks like for the next decade. - Pure telehealth, digital therapeutics, and AI-veneer companies without proprietary data or workflow defensibility are being actively rotated out of portfolios. - Saudi Arabia's healthcare investment thesis is shifting from consumer to producer economy — the terms of engagement for foreign companies are moving from market access to co-development and local presence.